Logo image of BBIO

BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

USA - NASDAQ:BBIO - US10806X1028 - Common Stock

51.21 USD
-1.39 (-2.64%)
Last: 9/12/2025, 8:00:01 PM
51.21 USD
0 (0%)
After Hours: 9/12/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BBIO. BBIO was compared to 542 industry peers in the Biotechnology industry. BBIO may be in some trouble as it scores bad on both profitability and health. BBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BBIO had negative earnings in the past year.
In the past year BBIO has reported a negative cash flow from operations.
BBIO had negative earnings in each of the past 5 years.
In the past 5 years BBIO always reported negative operating cash flow.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

BBIO's Return On Assets of -71.88% is on the low side compared to the rest of the industry. BBIO is outperformed by 63.28% of its industry peers.
Industry RankSector Rank
ROA -71.88%
ROE N/A
ROIC N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

BBIO has a Gross Margin of 96.19%. This is amongst the best in the industry. BBIO outperforms 95.02% of its industry peers.
In the last couple of years the Gross Margin of BBIO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BBIO has more shares outstanding than it did 1 year ago.
BBIO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BBIO has an improved debt to assets ratio.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

BBIO has an Altman-Z score of -3.35. This is a bad value and indicates that BBIO is not financially healthy and even has some risk of bankruptcy.
BBIO has a Altman-Z score (-3.35) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.35
ROIC/WACCN/A
WACC9.35%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

BBIO has a Current Ratio of 5.19. This indicates that BBIO is financially healthy and has no problem in meeting its short term obligations.
BBIO has a Current ratio of 5.19. This is comparable to the rest of the industry: BBIO outperforms 56.46% of its industry peers.
A Quick Ratio of 5.08 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a Quick ratio (5.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.19
Quick Ratio 5.08
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BBIO have decreased strongly by -64.64% in the last year.
BBIO shows a small growth in Revenue. In the last year, the Revenue has grown by 7.62%.
BBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.48% yearly.
EPS 1Y (TTM)-64.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.59%
Revenue 1Y (TTM)7.62%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%4999.86%

3.2 Future

The Earnings Per Share is expected to grow by 27.74% on average over the next years. This is a very strong growth
Based on estimates for the next years, BBIO will show a very strong growth in Revenue. The Revenue will grow by 64.96% on average per year.
EPS Next Y-11.02%
EPS Next 2Y13.74%
EPS Next 3Y23.27%
EPS Next 5Y27.74%
Revenue Next Year114.01%
Revenue Next 2Y88.2%
Revenue Next 3Y80.87%
Revenue Next 5Y64.96%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

BBIO's earnings are expected to grow with 23.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.74%
EPS Next 3Y23.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (9/12/2025, 8:00:01 PM)

After market: 51.21 0 (0%)

51.21

-1.39 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners86.19%
Inst Owner Change0.56%
Ins Owners4.34%
Ins Owner Change-7.62%
Market Cap9.79B
Analysts84.62
Price Target67.49 (31.79%)
Short Float %12.42%
Short Ratio7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.94%
Min EPS beat(2)-10.44%
Max EPS beat(2)6.56%
EPS beat(4)1
Avg EPS beat(4)-8.86%
Min EPS beat(4)-21.38%
Max EPS beat(4)6.56%
EPS beat(8)3
Avg EPS beat(8)8.72%
EPS beat(12)4
Avg EPS beat(12)4.03%
EPS beat(16)5
Avg EPS beat(16)6.44%
Revenue beat(2)2
Avg Revenue beat(2)51.6%
Min Revenue beat(2)18.58%
Max Revenue beat(2)84.61%
Revenue beat(4)3
Avg Revenue beat(4)35.03%
Min Revenue beat(4)-28.8%
Max Revenue beat(4)84.61%
Revenue beat(8)4
Avg Revenue beat(8)175.18%
Revenue beat(12)4
Avg Revenue beat(12)96.08%
Revenue beat(16)5
Avg Revenue beat(16)81.87%
PT rev (1m)5.36%
PT rev (3m)9.59%
EPS NQ rev (1m)0.08%
EPS NQ rev (3m)-0.81%
EPS NY rev (1m)-6.69%
EPS NY rev (3m)-6.2%
Revenue NQ rev (1m)-2.02%
Revenue NQ rev (3m)15.22%
Revenue NY rev (1m)4.67%
Revenue NY rev (3m)13.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.33
EYN/A
EPS(NY)-2.18
Fwd EYN/A
FCF(TTM)-3.49
FCFYN/A
OCF(TTM)-3.43
OCFYN/A
SpS1.23
BVpS-9.35
TBVpS-9.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.19%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
F-Score3
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 211.73%
Cap/Sales 4.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.19
Quick Ratio 5.08
Altman-Z -3.35
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)86.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.73%
Cap/Sales(5y)27.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.59%
EPS Next Y-11.02%
EPS Next 2Y13.74%
EPS Next 3Y23.27%
EPS Next 5Y27.74%
Revenue 1Y (TTM)7.62%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%4999.86%
Revenue Next Year114.01%
Revenue Next 2Y88.2%
Revenue Next 3Y80.87%
Revenue Next 5Y64.96%
EBIT growth 1Y-28.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.08%
EBIT Next 3Y30.23%
EBIT Next 5Y16.28%
FCF growth 1Y-36.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.92%
OCF growth 3YN/A
OCF growth 5YN/A